Minneapolis Veterans Affairs Medical Center

va.gov

Total trials

40

Active

4

Phase 3

6

Total enrollment

6,910

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 4 of 4 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
IV ketamine1
Midazolam1
Active tDCS and Cognitive Training Intervention1
Sham tDCS and Cognitive Training Intervention1

Next readouts

  • 2026-12
  • 2027-09

Top conditions

  • Traumatic Brain Injury4
  • Chronic Pain3
  • Type 2 Diabetes3
  • Alcoholism2
  • Impulsivity2
  • Diabetes Mellitus2
  • Osteoarthritis, Knee2
  • Arthritis2

Frequently asked questions about Minneapolis Veterans Affairs Medical Center

How many clinical trials does Minneapolis Veterans Affairs Medical Center have on ClinicalTrials.gov?
Minneapolis Veterans Affairs Medical Center is listed as the lead sponsor on 40 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
How many of Minneapolis Veterans Affairs Medical Center's trials are in Phase 3?
6 of Minneapolis Veterans Affairs Medical Center's trials are in Phase 3, spread across 4 active drug programs.
What therapeutic areas does Minneapolis Veterans Affairs Medical Center focus on?
Minneapolis Veterans Affairs Medical Center's most-studied conditions on ClinicalTrials.gov are Traumatic Brain Injury, Chronic Pain, Type 2 Diabetes, Alcoholism, Impulsivity.
When are Minneapolis Veterans Affairs Medical Center's next clinical trial readouts?
Minneapolis Veterans Affairs Medical Center has 2 upcoming primary-completion readouts tracked here; the soonest is “Ketamine Treatment for PTSD and MDD in TBI”, expected around 2026-12.